Department of Pathology and Cell Biology, Institute of Research in Immunology and Cancer (IRIC), Université de Montréal, Pavillion Marcelle-Coutu, Chemin Polytechnique, Montreal, QC, Canada.
Biomol NMR Assign. 2021 Oct;15(2):323-328. doi: 10.1007/s12104-021-10024-9. Epub 2021 Apr 18.
The human UDP-glucuronosyltransferase (UGT) family of enzymes catalyze the covalent addition of glucuronic acid to a wide range of compounds, generally rendering them inactive. Although important for clearance of environmental toxins and metabolites, UGT activation can lead to inappropriate glucuronidation of therapeutics underlying drug resistance. Indeed, 50% of medications are glucuronidated. To better understand this mode of resistance, we studied the UGT2B7 enzyme associated with glucuronidation of cancer drugs such as Tamoxifen and Sorafenib. We report H, C and N backbone (> 90%) and side-chain assignments (~ 78% completeness according to CYANA) for the C-terminal domain of UGT2B7 (UGT2B7-C). Given the biomedical importance of this family of enzymes, our assignments will provide a key tool for improving understanding of the biochemical basis for substrate selectivity and other aspects of enzyme activity. This in turn will inform on drug design to overcome UGT-related drug resistance.
人类尿苷二磷酸葡萄糖醛酸基转移酶 (UGT) 家族的酶催化将葡萄糖醛酸共价添加到广泛的化合物中,通常使它们失去活性。尽管对于清除环境毒素和代谢物很重要,但 UGT 的激活会导致治疗药物的不当葡萄糖醛酸化,从而导致药物耐药性。事实上,50%的药物都经过葡萄糖醛酸化。为了更好地理解这种耐药模式,我们研究了与癌症药物如他莫昔芬和索拉非尼的葡萄糖醛酸化相关的 UGT2B7 酶。我们报告了 UGT2B7(UGT2B7-C)C 末端结构域的 H、C 和 N 主链(>90%)和侧链分配(根据 CYANA 约为 78%的完整性)。鉴于这些酶家族在生物医学方面的重要性,我们的分配将为提高对底物选择性和酶活性其他方面的生化基础的理解提供关键工具。这反过来又将为克服与 UGT 相关的药物耐药性的药物设计提供信息。